Clinical Study

An Evaluation of Neoadjuvant Chemoradiotherapy for Patients with Resectable Pancreatic Ductal Adenocarcinoma

Table 3

Postoperative mortality and morbidity between the two groups.

ObjectsAll patientsGroup IGroup IIP values

Morbidity 29.3%27.7%30.8%0.123
Mortality3.02%2.67%3.33%0.123